Indolyl Aryl Sulphones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Synthesis,Biological Evaluation and Binding Mode Studies of New Derivatives at Indole-2-carboxamide
Free accessResearch articleFirst published online April, 2006
Indolyl Aryl Sulphones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Synthesis,Biological Evaluation and Binding Mode Studies of New Derivatives at Indole-2-carboxamide
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are active against the commonly occurring mutations of HIV are urgently needed for the treatment of AIDS. We synthesized new NNRTIs of the indolyl aryl sulphone (IAS) family, which are endowed with high antiviral potency against HIV-1 wt (wild-type), and the Y181C and K103N-Y181C drug resistant mutant strains. Several new compounds were highly active in lymphocytes infected with primary isolates carrying the K103N-V108I-M184V and L100I-V108I mutations. The design of new IASs was based on three-dimensional quantitative structure-activity relationship (3D QSAR) studies and docking simulations. A cross-docking study was also undertaken to gain some insights in to the binding mode of the newly synthesized IASs in the wt and mutated isoforms of reverse transcriptase.
AndreoniMSarmatiLParisiSGErcoliL & RocchiG (1992) Efficient and reproducible new semimicromethod for the detection and tritation of HIV in human plasma. Journal of Medical Virology38: 207–213.
2.
ArticoMSilvestriRMassaSLoiAGCorriasSPirasG & La CollaP (1996) 2-Sulfonyl-4-chloroanilino moiety: A potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. Journal of Medicinal Chemistry39: 522–530.
3.
ArticoMSilvestriRPagnozziEBrunoBNovellinoEGrecoGMassaSEttorreALoiAGScintuF & La CollaP (2000) Structure-based design, synthesis and biological evaluation of novel pyrrolyl aryl sulfones (PASs), HIV-1 non-nucleoside reverse tran-scriptase inhibitors active at nanomolar concentrationsJournal of Medicinal Chemistry43: 1886–1891.
4.
ArticoM (1996) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): A chemical survey from lead compounds to selected drugs for clinical trials. Farmaco51: 305–331.
BergaminiACapozziMGhibelliLDiniLSalanitroAMilaneseGWagnerTBeninatiSPesceCDAmiciC & RocchiG (1994) Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. Journal of Clinical Investigation93: 2251–2257.
7.
BermanHMWestbrookJFengZGillilandGBhatTNWeissigHShindyalovIN & BournePE (2000) The Protein Data Bank. Nucleic Acids Research28: 235–242.
8.
BlancaGBaldantiFPaolucciSSkoblovAYVictorovaLHübscherUGernaGSpadariS & MagaG (2003) Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity. Journal of Biological Chemistry18: 15469–15472.
9.
BuckheitRW (2001) Non-nucleoside reverse transcriptase inhibitors: Perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opinion on Investigational Drugs10: 1423–42.
10.
ChouTC (1976) Derivation and properties of Micaelis-Menten type and Hill type equation for reference ligands. Journal of Theoretical Biology59: 253–276.
11.
CorbettJW & RodgersJD (2002) Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1. Progress in Medicinal Chemistry40: 63–105.
12.
De ClercqE (2002) New anti-HIV agents and targets. Medicinal Research Reviews6: 531–565.
13.
De ClercqE (2004) Non-nucleoside anti-HIV-1 reverse transcriptase inhibitors (NNRTIs): Past, present and future. Chemistry & Biodiversity1: 44–64.
14.
De ClercqE (2005) New approaches toward anti-HIV chemotherapy. Journal of Medicinal Chemistry48: 1297–1313.
15.
GoodsellDSMorrisGM & OlsonAJ (1996) Automated docking of flexible ligands: Applications of AutoDock. Journal of Molecular Recognition9: 1–5.
16.
GuexN & PeitschMC (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modelling. Electrophoresis18: 2714–2723
17.
HuangCCCouchGSPettersenEF & FerrinTE (1996) In Chimera: An extensible molecular modelling application constructed using standard components, Pacific Symposium on Biocomputing, 724.
18.
KarberG (1931) Beitrag zur kollectiven Behandlung Pharmakologisher Reihenversuche [German] [Contribution to the collective treatment of pharmacological research]. Archive der Experimentell Pharmakologie162: 480–483.
19.
MagaGAmackerMRuelNHubsherU & SpadariS (1997) Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. Journal of Molecular Biology274: 738–747.
20.
McLachlanAD (1982) Rapid comparison of protein structures. Acta Crystallographica, Section A: Crystal physics, diffraction, theoretical and general crystallographyA38: 871–873
21.
MohamadiFRichardsNGJGuidaWCLiskampRLiptonMCaufieldCChangGHendricksonT & StillWC (1990) MacroModel-An Integrated Software System for Modelling Organic and Bioorganic Molecules Using Molecular Mechanics. Journal of Computational Chemistry11: 440–467.
22.
PauwelsRBalzariniJBabaMSnoeckRScholsDHederwijnPDesmysterJ & De ClercqE (1988). A rapid and automated tetra-zolium-based colorimetric assay for the detection of anti HIV compounds. Journal of Virological Methods20: 309–321.
23.
PearlmanDACaseDACaldwellJWRossSCheathamTEIIIDeBoltSFergusonDSeibelG & KollmanP (1995) ‘AMBER’, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to stimulate the structural and energetic properties of molecules. Computer Physics Communication91: 1–42.
24.
PernoCFYarchoanRCooneyDAHartmanNRGartnerSPopovicMHaoZGerrardTLWilsonYA & JohnsDG (1998) Inhibition of human immunodeficiency virus (HIV-17, HTLV-III-Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-didesoxynucleosides. Journal of Experimental Medicine168: 1111–1125.
25.
PlacidoRMancinoGAmendolaAMarianiFVendittiSPiacentiniMSanduzziABocchinoMLZembalaM & ColizziV (1997) Apoptosis of human monocytes/macrophages in Mycobacterium tubercolosis infection. Journal of Pathology181: 31–38.
26.
RagnoRArticoRDe MartinoGLa ReginaGColucciaADi PasqualiA & SilvestriR (2005G) Docking and 3–D QSAR Studies on Indolyl Aryl Sulfones (IASs). Binding Mode Exploration at the HIV-1 Reverse Transcriptase Non—Nucleoside Binding Site and Design of Highly Active N-(2–Hydroxyethyl)carboxamide and N-(2–Hydroxyethyl) carboxy hydrazide Derivatives. Journal of Medicinal Chemistry48: 213–223
27.
RagnoRFrascaSManettiFBrizziA & MassaS (2005b) HIV–1 Reverse trascriptase inhibition: Inclusion of ligand—induced fit by cross—docking studies. Journal of Medicinal Chemistry48: 200–212.
28.
RenJEsnoufRGarmanESomersDRossCKirbyIKeelingJDarbyGJonesY & StuartD (1995) High resolution structures of HIV–1 RT from four RT—inhibitor complexes. Nature Structural Biology2: 293–302.
29.
RenJMiltonJWeaverKLShortSAStuartDI & StammersDK (2000) Structural basis for the resilience of efavirenz (DMP–266) to drug resistance mutations in HIV–1 reverse transcriptase. Structure8: 1089–1094
30.
RenJNicholsCBirdLChamberlainPWeaverKShortSStuartDI & StammersDK (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV–1 reverse transcriptase and the improved resilience of second generation non—nucleoside inhibitors. Journal of Molecular Biology312: 795–805.
31.
RenJNicholsCEChamberlainPPWeaverKLShortSA & StammersDK (2004) Crystal structures of HIV–1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non—nucleoside inhibitors. Journal of Molecular Biology336: 569–578.
32.
SilvestriRArticoMDe MartinoGLa ReginaGLoddoRLa CollaM & La CollaP (2004) Simple, short peptide derivatives of L–737,126 active in vitro against HIV–1 WT and variants carrying NNRTI resistance mutations. Journal of Medicinal Chemistry47: 3892–3896.
33.
SilvestriRDe MartinoGArticoMMassaSMarcedduTLoiAGMusiuC & La CollaC (2003) Novel indolyl aryl sulfones active against HIV–1 carrying NNRTI resistance mutations: Synthesis and SAR studies. Journal of Medicinal Chemistry46: 2482–2493.
34.
SodroskiJGRosenCA & HaseltineWA (1984) Trans—acting trans-critional activation of the long terminal repeat of human lym-photropic viruses in infected cells. Science225: 381–385.
35.
TachedjianG & GoffSP (2003) The effect of NNRTIs on HIV reverse transcriptase dimerization. Current Opinion in Investigational Drugs4: 966–973.
36.
TetkoIV & TanchukVY (2002) Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program. Journal of Chemical Information and. Computer Sciences42: 1136–1145
37.
VandammeA-MVan VaerenberghK & De ClercqE (1998) Anti—human immunodeficiency virus drug combination strategies. Antiviral Chemistry & Chemotherapy. 9: 187–203.
38.
WHO/UNAIDS. AIDS Epidemic Update: December 2003.
39.
WilliamsIG (2003) Enfuvirtide (Fuzeon): The first fusion inhibitor. International Journal of Clinical Practice57: 890–897.
40.
WilliamsTMCiccaroneTMSaariWSWaiJSGreenleeWJBalaniSKGoldmanMEHoffmanJMJrLummaWCJrHuffJRooneyCSandersonPE & TheoharidesAD (1994) Indole derivatives as inhibitors of HIV reverse transcriptase. Patent PCT Int. Appl, WO 9419321.
